Page last updated: 2024-09-02

valerates and Fatty Liver, Nonalcoholic

valerates has been researched along with Fatty Liver, Nonalcoholic in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Chen, YE; Cheng, S; Garcia-Barrio, MT; Guo, X; He, Y; Huang, W; Ji, L; Liu, Z; Meng, X; Pan, B; Wang, L; Xiong, X; Xu, M; Yang, H; Yin, Y; Zhao, L; Zhao, M; Zheng, L	1
El-Awady, MS; Gameil, NM; Megahed, N; Sharawy, MH	1

Other Studies

2 other study(ies) available for valerates and Fatty Liver, Nonalcoholic

Article	Year
TMAVA, a Metabolite of Intestinal Microbes, Is Increased in Plasma From Patients With Liver Steatosis, Inhibits γ-Butyrobetaine Hydroxylase, and Exacerbates Fatty Liver in Mice. Gastroenterology, 2020, Volume: 158, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Bacteria; Biomarkers; Case-Control Studies; Cross-Sectional Studies; Diet, High-Fat; Dysbiosis; Fatty Acids, Nonesterified; Feces; Female; gamma-Butyrobetaine Dioxygenase; Gastrointestinal Microbiome; Humans; Intestines; Lipolysis; Liver; Male; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; Up-Regulation; Valerates; Young Adult	2020
The ergogenic supplement β-hydroxy-β-methylbutyrate (HMB) attenuates insulin resistance through suppressing GLUT-2 in rat liver. Canadian journal of physiology and pharmacology, 2016, Volume: 94, Issue:5 Topics: Animals; Dietary Carbohydrates; Dietary Supplements; Endothelium, Vascular; Fructose; Gene Expression Regulation; Glucose Intolerance; Glucose Transporter Type 2; Hyperinsulinism; Hyperlipidemias; Insulin Resistance; Liver; Male; Non-alcoholic Fatty Liver Disease; Performance-Enhancing Substances; PPAR alpha; Random Allocation; Rats, Sprague-Dawley; Sterol Regulatory Element Binding Protein 1; TOR Serine-Threonine Kinases; Valerates; Vascular Resistance	2016

Article

Year

TMAVA, a Metabolite of Intestinal Microbes, Is Increased in Plasma From Patients With Liver Steatosis, Inhibits γ-Butyrobetaine Hydroxylase, and Exacerbates Fatty Liver in Mice.

Gastroenterology, 2020, Volume: 158, Issue:8

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Bacteria; Biomarkers; Case-Control Studies; Cross-Sectional Studies; Diet, High-Fat; Dysbiosis; Fatty Acids, Nonesterified; Feces; Female; gamma-Butyrobetaine Dioxygenase; Gastrointestinal Microbiome; Humans; Intestines; Lipolysis; Liver; Male; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; Up-Regulation; Valerates; Young Adult

2020

The ergogenic supplement β-hydroxy-β-methylbutyrate (HMB) attenuates insulin resistance through suppressing GLUT-2 in rat liver.

Canadian journal of physiology and pharmacology, 2016, Volume: 94, Issue:5

Topics: Animals; Dietary Carbohydrates; Dietary Supplements; Endothelium, Vascular; Fructose; Gene Expression Regulation; Glucose Intolerance; Glucose Transporter Type 2; Hyperinsulinism; Hyperlipidemias; Insulin Resistance; Liver; Male; Non-alcoholic Fatty Liver Disease; Performance-Enhancing Substances; PPAR alpha; Random Allocation; Rats, Sprague-Dawley; Sterol Regulatory Element Binding Protein 1; TOR Serine-Threonine Kinases; Valerates; Vascular Resistance

2016